pharmaglobenews, Author at Pharma Globenewswire

IgG4-Related Disease Market Set to Surge at 34.60% CAGR, Reaching New Heights by 2034 Driven by Emerging Therapies and Rising Disease Awareness Globally

IgG4-Related Disease Market Summary The IgG4-Related Disease market is witnessing a transformative period of growth and clinical advancement. Valued at approximately USD 182 million in 2025 across the 7 Major Markets (7MM), the market is projected to expand at a remarkable CAGR

17 April 2026

Uncategorised

Inflammatory Myositis Market Set for Remarkable Growth: Projected CAGR of 11.7% Through 2034 Driven by Emerging Therapies and Rising Patient Demand Across Seven Major Markets

Inflammatory Myositis Market In 2023, the Inflammatory myositis market in the US stood out prominently among the seven major markets (7MM), reaching an impressive USD 301 million. This significant figure not only underscores the current robust demand but also highlights the substantial

16 April 2026

Uncategorised

Chronic Spontaneous Urticaria Market Set to Surpass USD 2000 Million by 2025, Driven by Emerging Biologics, Rising Disease Awareness, and Expanding Global Treatment Access

Chronic Spontaneous Urticaria Market Summary The Chronic Spontaneous Urticaria market has emerged as one of the most dynamically evolving segments within immunodermatology. The Chronic Spontaneous Urticaria market size in the 7 Major Markets (7MM) – comprising the United States, EU4 countries (Germany,

16 April 2026

Uncategorised

WHIM Syndrome Market: Epidemiology Insights, Emerging Therapies, Pipeline Analysis, and Growth Forecast Across the 7 Major Markets Through 2034

WHIM Syndrome Market The Whim Syndrome market is gaining increased attention from the global healthcare and pharmaceutical community as rare disease awareness expands and novel therapeutic approaches begin to emerge. WHIM syndrome is a rare genetic disorder caused by CXCR4 mutations, leading

14 April 2026

Uncategorised

Allergic Rhinitis Market Set to Surge Beyond USD 3,600 Million as Emerging Therapies and Rising Global Prevalence Drive Substantial Growth Through 2034

Allergic Rhinitis Market The Allergic Rhinitis market is witnessing a period of significant transformation, driven by rising disease prevalence, expanding treatment pipelines, and growing awareness across the seven major markets (7MM) – the United States, Germany, France, Italy, Spain, the United Kingdom,

13 April 2026

Uncategorised

Liver Cirrhosis Market: Size, Share, Trends, Emerging Therapies, Epidemiology, and Forecast 2024 – 2034

Liver Cirrhosis Market The Liver Cirrhosis market is witnessing substantial momentum as healthcare systems worldwide grapple with the rising burden of chronic liver disease. The Liver Cirrhosis market size in the 7 Major Markets (7MM) – comprising the United States, EU4 countries

12 April 2026

Uncategorised

Multiple Myeloma: Comprehensive Market Intelligence, Epidemiology, and Forecast Analysis Through 2034

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2034” analysis provides comprehensive understanding of Multiple Myeloma, encompassing historical and projected epidemiology alongside market trajectories across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan. The latest

10 April 2026

Uncategorised

Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch

Eczema Major players in the pipeline include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. DelveInsight’s “Eczema Pipeline Insights 2026” report delivers an extensive analysis

9 April 2026

Clinical Trials·Reports

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

DelveInsight’s “Lassa Fever – Pipeline Insight, 2026” provides a detailed view of the evolving pipeline, emphasizing efforts to deliver first-in-class therapies and vaccines to endemic populations. The report highlights global R&D activity, platform technologies, and regulatory incentives accelerating development timelines.Lassa Fever, an

9 April 2026

Clinical Trials·Reports

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise in aging populations is significantly increasing the at-risk patient base.

9 April 2026

pharmaglobenews

Inflammatory Myositis Market Set for Remarkable Growth: Projected CAGR of 11.7% Through 2034 Driven by Emerging Therapies and Rising Patient Demand Across Seven Major Markets

Chronic Spontaneous Urticaria Market Set to Surpass USD 2000 Million by 2025, Driven by Emerging Biologics, Rising Disease Awareness, and Expanding Global Treatment Access

WHIM Syndrome Market: Epidemiology Insights, Emerging Therapies, Pipeline Analysis, and Growth Forecast Across the 7 Major Markets Through 2034

Allergic Rhinitis Market Set to Surge Beyond USD 3,600 Million as Emerging Therapies and Rising Global Prevalence Drive Substantial Growth Through 2034

Liver Cirrhosis Market: Size, Share, Trends, Emerging Therapies, Epidemiology, and Forecast 2024 – 2034

Multiple Myeloma: Comprehensive Market Intelligence, Epidemiology, and Forecast Analysis Through 2034

Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

Recent Posts

Banner

Newsletter

Authors